DiaMedica Therapeutics (DMAC)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from DMAC's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from DiaMedica Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$14M | -$14M | -$19M | -$24M | -$33M |
| Free cash flow | -$12M | -$12M | -$19M | -$22M | -$29M |
| EPS (diluted) | -$0.65 | -$0.52 | -$0.60 | -$0.60 | -$0.70 |
| Operating margin | — | — | — | — | — |
Superinvestors who own DMAC
From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Trimmed | $78,333 | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by DiaMedica Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Nov 25, 2025 | Jan Stahlberg |
73,099 | $8.57 | $626,458 |
| Nov 24, 2025 | Jan Stahlberg |
40,253 | $7.89 | $317,596 |
| Nov 21, 2025 | Jan Stahlberg |
208,872 | $7.41 | $2M |
| Nov 20, 2025 | Jan Stahlberg |
128,426 | $7.41 | $951,637 |
| Nov 19, 2025 | Jan Stahlberg |
240,352 | $7.21 | $2M |
| Nov 18, 2025 | Jan Stahlberg |
182,882 | $6.75 | $1M |
| Nov 17, 2025 | Jan Stahlberg |
187,393 | $6.52 | $1M |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when DMAC trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are DiaMedica Therapeutics insiders buying the stock?
7 open-market insider purchases of DMAC in the last 12 months, from SEC Form 4 filings.
Which superinvestors own DiaMedica Therapeutics?
1 of the superinvestors Investingly tracks hold DMAC in their latest 13F, including Cliff Asness.
Companies like DiaMedica Therapeutics
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.